Overview Study of BHV-1400 in IgA Nephropathy Status: RECRUITING Trial end date: 2026-07-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).Phase: PHASE1 Details Lead Sponsor: Biohaven Therapeutics Ltd.